Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated Computational and Functional Screening Identifies G9a Inhibitors for SETD2-mutant Leukemia.

Genomics, proteomics & bioinformatics - 30 May 2025

Zhang Ya, Xia Mengfang, Yi Zhenyi, Sui Pinpin, He Xudong, Wang Liping, Chen Qiyi, Zhu Hong-Hu, Huang Gang, Wang Qian-Fei

Abstract excerpt

SETD2, a frequently mutated epigenetic tumor suppressor gene in acute leukemia, is associated with chemotherapy resistance and poor patient outcomes. To explore potential therapeutics for SETD2-mutant leukemia, we employed an integrated approach combining computational prediction with epigenetic compound library screening. This approach identified G9a inhibitors as promising candidates, capable of reversing gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Histocompatibility Antigens

Share to Histone-Lysine N-Methyltransferase

Share to Leukemia

Share to MicroRNAs

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 40300107
DOI: 10.1093/gpbjnl/qzaf035
PMCID: PMC12373973

Genes

SETD2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated Computational and Functional Screening Identifies G9a Inhibitors for SETD2-mutant Leukemia.PMID 40300107Read ↗

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia.Semantic proximity Read ↗

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cellsSemantic proximity Read ↗

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survivalSemantic proximity Read ↗

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survivalSemantic proximity Read ↗

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.Semantic proximity Read ↗

Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and BeyondSemantic proximity Read ↗

The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation.Semantic proximity Read ↗

Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance DevelopmentSemantic proximity Read ↗

Identification of functional cooperative mutations of SETD2 in human acute leukemia.Semantic proximity Read ↗

SETD2: an epigenetic modifier with tumor suppressor functionality.Semantic proximity Read ↗

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.